menu
    • menu
    [{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Antihemophilic factor recombinant","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Prime Therapeutics \/ Takeda","highestDevelopmentStatusID":"12","companyTruncated":"Prime Therapeutics \/ Takeda"}]

    Find Clinical Drug Pipeline Developments & Deals for Antihemophilic factor recombinant

    Menu

    Antihemophilic factor recombinant

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prime Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Prime Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antihemophilic factor recombinant

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Prime Therapeutics and Takeda Agree to Outcomes-Based Arrangement for Hemophilia A Treatment ADVATE®

                            Details : ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A. The arrangement between Prime and Takeda provides an opportunity to assess clinical outcomes and cost implications with an existing treatment for he...

                            Brand Name : ADVATE

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 16, 2020

                            Lead Product(s) : Antihemophilic factor recombinant

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth